A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone

Kenneth Blum, David Han, Edward J. Modestino, Scott Saunders, A. Kennison Roy, William Solomon Jacobs, Darryl S. Inaba, David Baron, Marlene Oscar-Berman, Mary Hauser, Rajendra D. Badgaiyan, David E. Smith, John Femino, Mark S. Gold

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Buprenorphine and naloxone (bup/nal), a combination partial mu receptor agonist and low-dose delta mu antagonist, is presently recommended and used to treat opioid-use disorder. However, a literature review revealed a paucity of research involving data from urine drug tests that looked at compliance and abstinence in one sample. Method: Statistical analysis of data from the Comprehensive Analysis of Reported Drugs (CARD) was used to assess compliance and abstinence during treatment in a large cohort of bup/nal patients attending chemical-dependency programs from eastern USA in 2010 and 2011. Results: Part 1: Bup/nal was present in 93.4% of first (n = 1,282; p <.0001) and 92.4% of last (n = 1,268; p <.0001) urine samples. Concomitantly, unreported illicit drugs were present in 47.7% (n = 655, p =.0261) of samples. Patients who were compliant to the bup/nal prescription were more likely than noncompliant patients to be abstinent during treatment (p =.0012; odds ratio = 1.69 with 95% confidence interval (1.210, 2.354). Part 2: An analysis of all samples collected in 2011 revealed a significant improvement in both compliance (p < 2.2 × 10−16) and abstinence (p < 2.2 × 10−16) during treatment. Conclusion/Importance: While significant use of illicit opioids during treatment with bup/nal is present, improvements in abstinence and high compliance during maintenance-assisted therapy programs may ameliorate fears of diversion in comprehensive programs. Expanded clinical datasets, the treatment modality, location, and year of sampling are important covariates, for further studies. The potential for long-term antireward effects from bup/nal use requires consideration in future investigations.

Original languageEnglish (US)
Pages (from-to)220-229
Number of pages10
JournalSubstance Use and Misuse
Volume53
Issue number2
DOIs
StatePublished - Jan 28 2018

Fingerprint

Street Drugs
addiction
Opioid Analgesics
Compliance
Substance-Related Disorders
drug
chemical dependency
Therapeutics
Urine
statistical analysis
medication
mu Opioid Receptor
confidence
anxiety
Pharmaceutical Preparations
Fear
Prescriptions
Naloxone Drug Combination Buprenorphine
Odds Ratio
Maintenance

Keywords

  • Abstinence
  • buprenorphine/naloxone
  • compliance
  • opioid maintenance therapy programs
  • substance-use disorder
  • urine drug screens

ASJC Scopus subject areas

  • Health(social science)
  • Medicine (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Psychiatry and Mental health

Cite this

A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone. / Blum, Kenneth; Han, David; Modestino, Edward J.; Saunders, Scott; Roy, A. Kennison; Jacobs, William Solomon; Inaba, Darryl S.; Baron, David; Oscar-Berman, Marlene; Hauser, Mary; Badgaiyan, Rajendra D.; Smith, David E.; Femino, John; Gold, Mark S.

In: Substance Use and Misuse, Vol. 53, No. 2, 28.01.2018, p. 220-229.

Research output: Contribution to journalArticle

Blum, K, Han, D, Modestino, EJ, Saunders, S, Roy, AK, Jacobs, WS, Inaba, DS, Baron, D, Oscar-Berman, M, Hauser, M, Badgaiyan, RD, Smith, DE, Femino, J & Gold, MS 2018, 'A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone', Substance Use and Misuse, vol. 53, no. 2, pp. 220-229. https://doi.org/10.1080/10826084.2017.1400064
Blum, Kenneth ; Han, David ; Modestino, Edward J. ; Saunders, Scott ; Roy, A. Kennison ; Jacobs, William Solomon ; Inaba, Darryl S. ; Baron, David ; Oscar-Berman, Marlene ; Hauser, Mary ; Badgaiyan, Rajendra D. ; Smith, David E. ; Femino, John ; Gold, Mark S. / A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone. In: Substance Use and Misuse. 2018 ; Vol. 53, No. 2. pp. 220-229.
@article{e0b9924f15d143b6a3d2507eedf4a644,
title = "A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone",
abstract = "Background: Buprenorphine and naloxone (bup/nal), a combination partial mu receptor agonist and low-dose delta mu antagonist, is presently recommended and used to treat opioid-use disorder. However, a literature review revealed a paucity of research involving data from urine drug tests that looked at compliance and abstinence in one sample. Method: Statistical analysis of data from the Comprehensive Analysis of Reported Drugs (CARD) was used to assess compliance and abstinence during treatment in a large cohort of bup/nal patients attending chemical-dependency programs from eastern USA in 2010 and 2011. Results: Part 1: Bup/nal was present in 93.4{\%} of first (n = 1,282; p <.0001) and 92.4{\%} of last (n = 1,268; p <.0001) urine samples. Concomitantly, unreported illicit drugs were present in 47.7{\%} (n = 655, p =.0261) of samples. Patients who were compliant to the bup/nal prescription were more likely than noncompliant patients to be abstinent during treatment (p =.0012; odds ratio = 1.69 with 95{\%} confidence interval (1.210, 2.354). Part 2: An analysis of all samples collected in 2011 revealed a significant improvement in both compliance (p < 2.2 × 10−16) and abstinence (p < 2.2 × 10−16) during treatment. Conclusion/Importance: While significant use of illicit opioids during treatment with bup/nal is present, improvements in abstinence and high compliance during maintenance-assisted therapy programs may ameliorate fears of diversion in comprehensive programs. Expanded clinical datasets, the treatment modality, location, and year of sampling are important covariates, for further studies. The potential for long-term antireward effects from bup/nal use requires consideration in future investigations.",
keywords = "Abstinence, buprenorphine/naloxone, compliance, opioid maintenance therapy programs, substance-use disorder, urine drug screens",
author = "Kenneth Blum and David Han and Modestino, {Edward J.} and Scott Saunders and Roy, {A. Kennison} and Jacobs, {William Solomon} and Inaba, {Darryl S.} and David Baron and Marlene Oscar-Berman and Mary Hauser and Badgaiyan, {Rajendra D.} and Smith, {David E.} and John Femino and Gold, {Mark S.}",
year = "2018",
month = "1",
day = "28",
doi = "10.1080/10826084.2017.1400064",
language = "English (US)",
volume = "53",
pages = "220--229",
journal = "Substance Use and Misuse",
issn = "1082-6084",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone

AU - Blum, Kenneth

AU - Han, David

AU - Modestino, Edward J.

AU - Saunders, Scott

AU - Roy, A. Kennison

AU - Jacobs, William Solomon

AU - Inaba, Darryl S.

AU - Baron, David

AU - Oscar-Berman, Marlene

AU - Hauser, Mary

AU - Badgaiyan, Rajendra D.

AU - Smith, David E.

AU - Femino, John

AU - Gold, Mark S.

PY - 2018/1/28

Y1 - 2018/1/28

N2 - Background: Buprenorphine and naloxone (bup/nal), a combination partial mu receptor agonist and low-dose delta mu antagonist, is presently recommended and used to treat opioid-use disorder. However, a literature review revealed a paucity of research involving data from urine drug tests that looked at compliance and abstinence in one sample. Method: Statistical analysis of data from the Comprehensive Analysis of Reported Drugs (CARD) was used to assess compliance and abstinence during treatment in a large cohort of bup/nal patients attending chemical-dependency programs from eastern USA in 2010 and 2011. Results: Part 1: Bup/nal was present in 93.4% of first (n = 1,282; p <.0001) and 92.4% of last (n = 1,268; p <.0001) urine samples. Concomitantly, unreported illicit drugs were present in 47.7% (n = 655, p =.0261) of samples. Patients who were compliant to the bup/nal prescription were more likely than noncompliant patients to be abstinent during treatment (p =.0012; odds ratio = 1.69 with 95% confidence interval (1.210, 2.354). Part 2: An analysis of all samples collected in 2011 revealed a significant improvement in both compliance (p < 2.2 × 10−16) and abstinence (p < 2.2 × 10−16) during treatment. Conclusion/Importance: While significant use of illicit opioids during treatment with bup/nal is present, improvements in abstinence and high compliance during maintenance-assisted therapy programs may ameliorate fears of diversion in comprehensive programs. Expanded clinical datasets, the treatment modality, location, and year of sampling are important covariates, for further studies. The potential for long-term antireward effects from bup/nal use requires consideration in future investigations.

AB - Background: Buprenorphine and naloxone (bup/nal), a combination partial mu receptor agonist and low-dose delta mu antagonist, is presently recommended and used to treat opioid-use disorder. However, a literature review revealed a paucity of research involving data from urine drug tests that looked at compliance and abstinence in one sample. Method: Statistical analysis of data from the Comprehensive Analysis of Reported Drugs (CARD) was used to assess compliance and abstinence during treatment in a large cohort of bup/nal patients attending chemical-dependency programs from eastern USA in 2010 and 2011. Results: Part 1: Bup/nal was present in 93.4% of first (n = 1,282; p <.0001) and 92.4% of last (n = 1,268; p <.0001) urine samples. Concomitantly, unreported illicit drugs were present in 47.7% (n = 655, p =.0261) of samples. Patients who were compliant to the bup/nal prescription were more likely than noncompliant patients to be abstinent during treatment (p =.0012; odds ratio = 1.69 with 95% confidence interval (1.210, 2.354). Part 2: An analysis of all samples collected in 2011 revealed a significant improvement in both compliance (p < 2.2 × 10−16) and abstinence (p < 2.2 × 10−16) during treatment. Conclusion/Importance: While significant use of illicit opioids during treatment with bup/nal is present, improvements in abstinence and high compliance during maintenance-assisted therapy programs may ameliorate fears of diversion in comprehensive programs. Expanded clinical datasets, the treatment modality, location, and year of sampling are important covariates, for further studies. The potential for long-term antireward effects from bup/nal use requires consideration in future investigations.

KW - Abstinence

KW - buprenorphine/naloxone

KW - compliance

KW - opioid maintenance therapy programs

KW - substance-use disorder

KW - urine drug screens

UR - http://www.scopus.com/inward/record.url?scp=85038403400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038403400&partnerID=8YFLogxK

U2 - 10.1080/10826084.2017.1400064

DO - 10.1080/10826084.2017.1400064

M3 - Article

VL - 53

SP - 220

EP - 229

JO - Substance Use and Misuse

JF - Substance Use and Misuse

SN - 1082-6084

IS - 2

ER -